Esai and Biogen’s Leqembi and Eli Lilly’s Kisunla target the amyloid beta protein clumps in the brain. Alzheimer’s affects more than 6 million Americans and is the country’s seventh-leading cause of death.
The treatments are “a double, not a home run,” Jeffrey Maneval, an assistant professor of neurology at Philadelphia-based University of Pennsylvania’s Perelman School of Medicine, told the newspaper. “But you have to get on base.”
Despite the optimism surrounding the treatments, however, some medical professionals remain cautious as the therapies come with significant price tags: the annual costs of Lequembi and Kisunla are approximately $26,500 and $32,000, respectively. There has also been concern with potential side effects, including brain bleeding, according to the report.
In addition to the new drug therapies, researchers are exploring the potential of blood tests to simplify and enhance the diagnosis of Alzheimer’s, the Post said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.